Tenosynovial Giant Cell Tumors Market to Exhibit Substantial Growth Rate During the Forecast Period | Elixiron, Daiichi Sankyo, Ammax Bio, Deciphera

As per DelveInsight, the Tenosynovial Giant Cell Tumors therapeutics market is anticipated to grow in the coming years owing to the increasing incident population of TSGCTs and the launch of the emerging drug in the 7MM.

Companies across the globe are diligently working toward developing novel treatment therapies with a considerable amount of success over the years. Key players, such as AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others, are actively working in the TSGCTs market. Emerging novel therapies like AMB-05X, Vimseltinib, and others are awaiting approval. These emerging therapies are in the mid and late phases of clinical trials, holding significant promise and potential to manage the disease burden.

DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tenosynovial Giant Cell Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Tenosynovial Giant Cell Tumors market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Read more baout TGCT Market @ https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent advancements in the Tenosynovial Giant Cell Tumors Market:

Deciphera Pharmaceuticals expects to submit New Drug Application (NDA) to the US FDA for vimseltinib in the second quarter of 2024 and Marketing Authorisation Application (MAA) to EMA in the third quarter of 2024 for tenosynovial giant cell tumor (TGCT).
In August 2022, EMA designated emactuzumab as an orphan medicinal product for both types (localized and diffuse) of TGCT.
In April 2024, SynOx Therapeutics raised USD 75 million in Series B financing. This fund will be used to generate registrational Phase 3 clinical and chemistry, manufacutirng and controls (CMC) data for emactuzumab, a CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).

Tenosynovial Giant Cell Tumors Overview

Tenosynovial giant cell tumors (TGCT) are rare, chronic conditions that affect the synovium, tendon sheaths, and bursa membranes, primarily in the knee, hip, and ankle joints. TGCTs exhibit a wide clinical spectrum and can affect individuals of all ages. The signs and symptoms of TGCT vary depending on the specific location and subtype involved.

TGCT is caused by a translocation of parts of chromosomes 1 and 2, leading to the overproduction of a protein called colony-stimulating factor-1 (CSF-1).

There are no conclusive environmental, genetic, occupational, lifestyle, demographic, or regional risk factors associated with the development of TGCT. The condition appears to occur sporadically without a clear link to any external influences.

Key Highlights from the Tenosynovial Giant Cell Tumors Market Report:

The 7MM had a Tenosynovial giant cell tumor market size of nearly USD 300 million in 2023. Among the 7MM, the highest market size was covered by the US, which was followed by Japan.
Tenosynovial giant cell tumor (TGCT) are rare, locally aggressive, typically benign neoplasms of joints, bursae, and tendon sheaths. TGCT can be roughly divided into localized and diffused types. Giant cell tumor of tendon sheath is the most common form of TGCT.
According to DelveInsight's epidemiology model, total prevalent cases of tenosynovial giant cell tumor (TGCT) was around 580,000 in seven major markets (7MM) in 2023. Among the 7MM, the United States accounted for the highest prevalent cases of tenosynovial giant cell tumor (TGCT) with approximately 40% of the total prevalent cases.
Surgical resection continues to be the mainstay of treatment for patients with localized and diffused TGCT. The significant rates of recurrence and risks associated with surgery point to the need for novel systemic treatments for patients with symptomatic advanced TGCT.
First systemic therapy to treat TGCT, i.e. TURALIO (pexidartinib) was approved by the US Food and Drug Administration (FDA) in August 2019. Moreover, various off-label therapies such as imatinib, sunitinib, and others are used frequently in the clinical settings.
Currently, there are no approved treatment for TGCT in Europe as Europen Medicine Agency (EMA) recommended the refusal of the marketing authorization for TURALIO (pexidartinib) due to serious concern about unpredictable, potentially life-threatening effects of TURALIO on the liver and uncertainity over the efficacy of the drug in July 2020.
Emerging therapies such as DCC-3014 (vimseltinib) and emactuzumab-developed by Deciphera Pharmaceuticals and SynOx Therapeutics (Celleron Therapeutics), respectively-are anticipated to dominate the TGCT market during the forecast period.
In the 7MM, Localised TGCT accounted for around 80% of the total cases of TGCT in 2023.
The tumor localization of localized TGCT in the 7MM was found to be maximum in the digits, which accounted for approximately 75% of the total cases in 2023.
The giant cell tumors are detected in the knee, ankle, hip, and other depending upon localized or diffused. DelveInsight has estimated tumor localization of diffused TGCT to be maximum in the knee, with nearly 30,000 cases in 2023 in the United States.
The gender-specific prevalent population of TGCT is segregated based on the tumor's growth pattern, i.e., localized and diffused form. As per DelveInsight's estimate, localized form was more prevalent in female than male, while the diffused form was evenly distributed among males and females.

To know more interesting facts about tensoynovial giant cell tumors market, visit: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Tenosynovial Giant Cell Tumors Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Tenosynovial Giant Cell Tumors market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Tenosynovial Giant Cell Tumors market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Tenosynovial Giant Cell Tumors Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.

The Report Covers the Tenosynovial Giant Cell Tumors Epidemiology, Segmented as -

Incident cases of Tenosynovial Giant Cell Tumor (TSGCTs) in the 7MM (2020-2034)
Gender-specific Incident cases of Tenosynovial Giant Cell Tumor (Land D-TSGCTs) in the 7MM (2020-2034)
Growth Pattern-specific Incident cases of Tenosynovial Giant Cell Tumor (TSGCTs) in the 7MM (2020-2034)
Tumor Localization of Tenosynovial Giant Cell Tumor (L and D-TSGCTs) in the 7MM (2020-2034)
Tenosynovial Giant Cell Tumors Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Tenosynovial Giant Cell Tumors market or expected to be launched during the study period. The analysis covers the Tenosynovial Giant Cell Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tenosynovial Giant Cell Tumors pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Tenosynovial Giant Cell Tumors Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Tenosynovial Giant Cell Tumors Therapeutics Analysis

Several pharma giants such as Elixiron, Daiichi Sankyo, Ammax Bio, Deciphera, and others are developing therapies for Tenosynovial Giant Cell Tumors. Currently, Deciphera Pharmaceutical is leading the therapeutics market with its Tenosynovial Giant Cell Tumors drug candidates in the most advanced stage of clinical development.

Key Companies in the Tenosynovial Giant Cell Tumors Therapeutics Market Include:

Abbisko Therapeutics Co, Ltd.
AmMax Bio, Inc.
Daiichi Sankyo
Deciphera Pharmaceuticals
Elixiron Immunotherapeutics
Hutchison Medipharma Limited
SynOx Therapeutics

Tenosynovial Giant Cell Tumors Emerging and Marketed Drugs Covered in the Report Include:

Vimseltinib: Deciphera Pharmaceuticals
EI-1071: Elixiron Immunotherapeutics
TURALIO (pexidartinib): Daiichi Sankyo
AMB-05X: AmMax Bio, Inc.

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Key Insights

2. Executive Summary

3. Tenosynovial Giant Cell Tumors Competitive Intelligence Analysis

4. Tenosynovial Giant Cell Tumors Market Overview at a Glance

5. Tenosynovial Giant Cell Tumors Disease Background and Overview

6. Tenosynovial Giant Cell Tumors Patient Journey

7. Tenosynovial Giant Cell Tumors Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Tenosynovial Giant Cell Tumors Treatment Algorithm, Current Treatment, and Medical Practices

9. Tenosynovial Giant Cell Tumors Unmet Needs

10. Key Endpoints of Tenosynovial Giant Cell Tumors Treatment

11. Tenosynovial Giant Cell Tumors Marketed Products

12. Tenosynovial Giant Cell Tumors Emerging Drugs and Latest Therapeutic Advances

13. Tenosynovial Giant Cell Tumors Seven Major Market Analysis

14. Attribute Analysis

15. Tenosynovial Giant Cell Tumors Market Outlook (In US, EU5, and Japan)

16. Tenosynovial Giant Cell Tumors Access and Reimbursement Overview

17. KOL Views on the Tenosynovial Giant Cell Tumors Market

18. Tenosynovial Giant Cell Tumors Market Drivers

19. Tenosynovial Giant Cell Tumors Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download sample pages @ https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:
Kritika Rehani
krehani@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.